BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

537 related articles for article (PubMed ID: 21727167)

  • 1. Non-steroidal anti-inflammatory drug use and risk of atrial fibrillation or flutter: population based case-control study.
    Schmidt M; Christiansen CF; Mehnert F; Rothman KJ; Sørensen HT
    BMJ; 2011 Jul; 343():d3450. PubMed ID: 21727167
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Glucocorticoid use and risk of atrial fibrillation or flutter: a population-based, case-control study.
    Christiansen CF; Christensen S; Mehnert F; Cummings SR; Chapurlat RD; Sørensen HT
    Arch Intern Med; 2009 Oct; 169(18):1677-83. PubMed ID: 19822824
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Risk of hospitalization for myocardial infarction among users of rofecoxib, celecoxib, and other NSAIDs: a population-based case-control study.
    Johnsen SP; Larsson H; Tarone RE; McLaughlin JK; Nørgård B; Friis S; Sørensen HT
    Arch Intern Med; 2005 May; 165(9):978-84. PubMed ID: 15883235
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prescription channeling of COX-2 inhibitors and traditional nonselective nonsteroidal anti-inflammatory drugs: a population-based case-control study.
    Moride Y; Ducruet T; Boivin JF; Moore N; Perreault S; Zhao S
    Arthritis Res Ther; 2005; 7(2):R333-42. PubMed ID: 15743481
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hospitalization for peptic ulcer and bleeding in users of selective COX-2 inhibitors and nonselective NSAIDs with special reference to celecoxib.
    Patterson MK; Castellsague J; Walker AM
    Pharmacoepidemiol Drug Saf; 2008 Oct; 17(10):982-8. PubMed ID: 18711705
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Possible link between history of hypersensitivity to a specific non-steroidal anti-inflammatory drug (NSAID) and positive results following challenge test to alternative NSAIDS.
    Trombetta D; Imbesi S; Vita G; Isola S; Minciullo PL; Saija A; Gangemi S
    Arzneimittelforschung; 2009; 59(8):410-4. PubMed ID: 19813464
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cardiovascular outcomes in new users of coxibs and nonsteroidal antiinflammatory drugs: high-risk subgroups and time course of risk.
    Solomon DH; Avorn J; Stürmer T; Glynn RJ; Mogun H; Schneeweiss S
    Arthritis Rheum; 2006 May; 54(5):1378-89. PubMed ID: 16645966
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Gastrointestinal and cardiovascular risk of non-selective NSAIDs and COX-2 inhibitors in elderly patients with knee osteoarthritis.
    Turajane T; Wongbunnak R; Patcharatrakul T; Ratansumawong K; Poigampetch Y; Songpatanasilp T
    J Med Assoc Thai; 2009 Dec; 92 Suppl 6():S19-26. PubMed ID: 20128070
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 30-day mortality after peptic ulcer perforation among users of newer selective COX-2 inhibitors and traditional NSAIDs: a population-based study.
    Thomsen RW; Riis A; Munk EM; Nørgaard M; Christensen S; Sørensen HT
    Am J Gastroenterol; 2006 Dec; 101(12):2704-10. PubMed ID: 17026569
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Risk of upper gastrointestinal complications associated with cyclooxygenase-2 selective and nonselective nonsteroidal antiinflammatory drugs.
    Castellsague J; Holick CN; Hoffman CC; Gimeno V; Stang MR; Perez-Gutthann S
    Pharmacotherapy; 2009 Dec; 29(12):1397-407. PubMed ID: 19947799
    [TBL] [Abstract][Full Text] [Related]  

  • 11. COX-2-selective inhibitors and the risk of upper gastrointestinal bleeding in high-risk patients with previous gastrointestinal diseases: a population-based case-control study.
    Nørgård B; Pedersen L; Johnsen SP; Tarone RE; McLaughlin JK; Friis S; Sørensen HT
    Aliment Pharmacol Ther; 2004 Apr; 19(7):817-25. PubMed ID: 15043523
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Trends in incidence and mortality in the hospital diagnosis of atrial fibrillation or flutter in Denmark, 1980-1999.
    Frost L; Vestergaard P; Mosekilde L; Mortensen LS
    Int J Cardiol; 2005 Aug; 103(1):78-84. PubMed ID: 15922465
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Risk of upper gastrointestinal bleeding with oral bisphosphonates and non steroidal anti-inflammatory drugs: a case-control study.
    Etminan M; Lévesque L; Fitzgerald JM; Brophy JM
    Aliment Pharmacol Ther; 2009 Jun; 29(11):1188-92. PubMed ID: 19298582
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nonsteroidal antiinflammatory drug use and cardiovascular risks after coronary stent implantation.
    Schmidt M; Pedersen L; Maeng M; Lassen JF; Lash TL; Nielsen TT; Sørensen HT
    Pharmacotherapy; 2011 May; 31(5):458-68. PubMed ID: 21923427
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Risk of death or reinfarction associated with the use of selective cyclooxygenase-2 inhibitors and nonselective nonsteroidal antiinflammatory drugs after acute myocardial infarction.
    Gislason GH; Jacobsen S; Rasmussen JN; Rasmussen S; Buch P; Friberg J; Schramm TK; Abildstrom SZ; Køber L; Madsen M; Torp-Pedersen C
    Circulation; 2006 Jun; 113(25):2906-13. PubMed ID: 16785336
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The balance between severe cardiovascular and gastrointestinal events among users of selective and non-selective non-steroidal anti-inflammatory drugs.
    van der Linden MW; van der Bij S; Welsing P; Kuipers EJ; Herings RM
    Ann Rheum Dis; 2009 May; 68(5):668-73. PubMed ID: 18495734
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Risk of adverse gastrointestinal outcomes in patients taking cyclo-oxygenase-2 inhibitors or conventional non-steroidal anti-inflammatory drugs: population based nested case-control analysis.
    Hippisley-Cox J; Coupland C; Logan R
    BMJ; 2005 Dec; 331(7528):1310-6. PubMed ID: 16322018
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hyperthyroidism and risk of atrial fibrillation or flutter: a population-based study.
    Frost L; Vestergaard P; Mosekilde L
    Arch Intern Med; 2004 Aug 9-23; 164(15):1675-8. PubMed ID: 15302638
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A regional audit of the use of COX-2 selective non-steroidal anti-inflammatory drugs (NSAIDs) in rheumatology clinics in the West Midlands, in relation to NICE guidelines.
    Price-Forbes AN; Callaghan R; Allen ME; Rowe IF
    Rheumatology (Oxford); 2005 Jul; 44(7):921-4. PubMed ID: 15827035
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Risks and benefits of COX-2 inhibitors vs non-selective NSAIDs: does their cardiovascular risk exceed their gastrointestinal benefit? A retrospective cohort study.
    Rahme E; Nedjar H
    Rheumatology (Oxford); 2007 Mar; 46(3):435-8. PubMed ID: 17255138
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.